Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 223

1.

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.

Hirota M, Shimosegawa T, Kitamura K, Takeda K, Takeyama Y, Mayumi T, Ito T, Takenaka M, Iwasaki E, Sawano H, Ishida E, Miura S, Masamune A, Nakai Y, Mitoro A, Maguchi H, Kimura K, Sanuki T, Ito T, Haradome H, Kozaka K, Gabata T, Kataoka K, Hirota M, Isaji S, Nakamura R, Yamagiwa K, Kayaba C, Ikeda K.

J Gastroenterol. 2020 Mar;55(3):342-352. doi: 10.1007/s00535-019-01644-z. Epub 2019 Nov 22.

PMID:
31758329
2.

Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Lee L, Ito T, Jensen RT.

Expert Rev Anticancer Ther. 2019 Dec;19(12):1029-1050. doi: 10.1080/14737140.2019.1693893. Epub 2019 Nov 27.

PMID:
31738624
3.

Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Lee L, Ramos-Alvarez I, Ito T, Jensen RT.

Int J Mol Sci. 2019 Oct 16;20(20). pii: E5128. doi: 10.3390/ijms20205128. Review.

4.

Intravoxel incoherent motion magnetic resonance imaging for assessment of chronic pancreatitis with special focus on its early stage.

Fujita N, Nishie A, Asayama Y, Ishigami K, Fujimori N, Ito T, Honda H.

Acta Radiol. 2019 Sep 2:284185119872687. doi: 10.1177/0284185119872687. [Epub ahead of print] No abstract available.

PMID:
31475847
5.

Superparamagnetic iron-oxide-enhanced diffusion-weighted magnetic resonance imaging for the diagnosis of intrapancreatic accessory spleen.

Ishigami K, Nishie A, Nakayama T, Asayama Y, Kakihara D, Fujita N, Ushijima Y, Okamoto D, Ohtsuka T, Mori Y, Ito T, Mochidome N, Honda H.

Abdom Radiol (NY). 2019 Oct;44(10):3325-3335. doi: 10.1007/s00261-019-02189-8.

PMID:
31420705
6.

Prospective study of early chronic pancreatitis diagnosed based on the Japanese diagnostic criteria.

Masamune A, Nabeshima T, Kikuta K, Hamada S, Nakano E, Kume K, Kanno A, Sato A, Tachibana Y, Inatomi O, Yamamoto S, Ikeura T, Futagami S, Taguchi M, Hanada K, Shimizu K, Kageoka M, Saito T, Eguchi T, Kubota K, Takenaka M, Mima A, Irisawa A, Ito T, Andoh A, Inui K, Takeyama Y, Yamaue H, Okazaki K, Shimosegawa T.

J Gastroenterol. 2019 Oct;54(10):928-935. doi: 10.1007/s00535-019-01602-9. Epub 2019 Jul 3.

PMID:
31270692
7.

CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.

Miki M, Oono T, Fujimori N, Takaoka T, Kawabe K, Miyasaka Y, Ohtsuka T, Saito D, Nakamura M, Ohkawa Y, Oda Y, Suyama M, Ito T, Ogawa Y.

Cancer Med. 2019 Jul;8(8):3748-3760. doi: 10.1002/cam4.2232. Epub 2019 May 25.

8.

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.

Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M.

Invest New Drugs. 2019 Jun;37(3):591. doi: 10.1007/s10637-019-00757-9.

9.

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study.

Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y.

Onco Targets Ther. 2019 Feb 28;12:1717-1728. doi: 10.2147/OTT.S182259. eCollection 2019.

10.

Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.

Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N.

Ann Surg Oncol. 2019 May;26(5):1385-1393. doi: 10.1245/s10434-019-07252-8. Epub 2019 Mar 12.

PMID:
30863939
11.

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.

Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, Sawaki A, Okusaka T.

Jpn J Clin Oncol. 2019 Apr 1;49(4):354-360. doi: 10.1093/jjco/hyz009.

12.

Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan.

Yasuda H, Kataoka K, Takeyama Y, Takeda K, Ito T, Mayumi T, Isaji S, Mine T, Kitagawa M, Kiriyama S, Sakagami J, Masamune A, Inui K, Hirano K, Akashi R, Yokoe M, Sogame Y, Okazaki K, Morioka C, Kihara Y, Kawa S, Tanaka M, Andoh A, Kimura W, Nishimori I, Furuse J, Yokota I, Shimosegawa T.

World J Gastroenterol. 2019 Jan 7;25(1):107-117. doi: 10.3748/wjg.v25.i1.107.

13.

Risk Factors for Pancreatic Stone Formation in Type 1 Autoimmune Pancreatitis: A Long-term Japanese Multicenter Analysis of 624 Patients.

Ito T, Kawa S, Matsumoto A, Kubota K, Kamisawa T, Okazaki K, Hirano K, Hirooka Y, Uchida K, Masuda A, Ohara H, Shimizu K, Arakura N, Masamune A, Kanno A, Sakagami J, Itoi T, Ito T, Ueki T, Nishino T, Inui K, Mizuno N, Yoshida H, Sugiyama M, Iwasaki E, Irisawa A, Shimosegawa T, Chiba T.

Pancreas. 2019 Jan;48(1):49-54. doi: 10.1097/MPA.0000000000001210.

PMID:
30540679
14.

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study.

Sato K, Toyoshima Y, Moriyama S, Endo Y, Ito T, Ohki E.

Cancer Chemother Pharmacol. 2019 Jan;83(1):201-207. doi: 10.1007/s00280-018-3724-3. Epub 2018 Nov 9.

15.

Gastrinomas: Medical or Surgical Treatment.

Norton JA, Foster DS, Ito T, Jensen RT.

Endocrinol Metab Clin North Am. 2018 Sep;47(3):577-601. doi: 10.1016/j.ecl.2018.04.009. Review.

16.

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.

Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komoto I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobayashi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horiguchi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Senju M, Arioka H, Hara K, Imamura M, Okusaka T.

Cancer Chemother Pharmacol. 2018 Oct;82(4):661-668. doi: 10.1007/s00280-018-3656-y. Epub 2018 Jul 27.

PMID:
30054710
17.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.

Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10.

PMID:
29991024
18.

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Lee L, Ito T, Jensen RT.

Expert Rev Anticancer Ther. 2018 Sep;18(9):837-860. doi: 10.1080/14737140.2018.1496822. Epub 2018 Jul 17. Review.

19.

Using CRISPR/Cas9 to Knock out Amylase in Acinar Cells Decreases Pancreatitis-Induced Autophagy.

Yasunaga K, Ito T, Miki M, Ueda K, Fujiyama T, Tachibana Y, Fujimori N, Kawabe K, Ogawa Y.

Biomed Res Int. 2018 May 17;2018:8719397. doi: 10.1155/2018/8719397. eCollection 2018.

20.

Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Lee L, Ito T, Jensen RT.

Expert Opin Pharmacother. 2018 Jun;19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24.

Supplemental Content

Loading ...
Support Center